Search filters

List of works by Joyce O'Shaughnessy

"New" metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy

scientific article

A Pilot Study of Dose Intense Doxorubicin and Cyclophosphamide Followed by Infusional Paclitaxel in High-Risk Primary Breast Cancer ⬇️

scientific article published on 01 September 2003

A decade of letrozole: FACE

scientific article

A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients

scientific article

A four-gene decision tree signature classification of triple-negative breast cancer: Implications for targeted therapeutics

article

A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.

scientific article

A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer

scientific article published on 12 April 2013

A phase I study of sequential versus concurrent interleukin-3 and granulocyte-macrophage colony-stimulating factor in advanced breast cancer patients treated with FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy ⬇️

scientific article published on October 15, 1995

A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies.

scientific article

A phase II trial of pemetrexed and gemcitabine in patients with metastatic breast cancer who have received prior taxane therapy

scientific article published in April 2010

A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib

scientific article published on 22 July 2017

A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4).

scientific article

A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation.

scientific article published on 19 April 2018

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

scientific article published on 20 September 2020

Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer

scientific article published on 26 March 2019

Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer

scientific article

Abstract P5-19-09: Preliminary results from a phase 2 single-arm study of enzalutamide, an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC)

Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer

scientific article in 2015

Acute arterial thrombosis in a patient with breast cancer after chemotherapy with 5-fluorouracil, doxorubicin, leucovorin, cyclophosphamide, and interleukin-3

scientific article published on 01 November 1994

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial

scientific article published on 28 February 2018

Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study

scientific article

Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: a pilot study ⬇️

scientific article published on October 14, 2010

Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial

scientific article published on 10 December 2012

Advancing the Field of Breast Cancer Care

scientific article published on 10 April 2020

Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis

scientific article published on 04 October 2011

Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis

scientific article published on 01 July 2019

Amendment to clinical research projects. Genetic marking with retroviral vectors to study the feasibility of stem cell gene transfer and the biology of hematopoietic reconstitution after autologous transplantation in multiple myeloma, chronic myelog

scientific article published on 01 April 1993

Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).

scientific article published on 11 April 2017

Arterial thrombosis associated with granulocyte-macrophage colony-stimulating factor (GM-CSF) administration in breast cancer patients treated with dose-intensive chemotherapy: a report of two cases

scientific article published on January 1995

Association of Pathological Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-analysis

scientific article published on 14 September 2020

BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib

scientific article

Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs

scientific article published on 26 November 2019

Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation

scientific article published on 4 November 2016

Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor-Positive Metastatic Breast Cancer

scientific article published on 7 June 2016

Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer

scientific article published in February 2002

Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results From the BrighTNess Randomized Clinical Trial

scientific article published on 08 January 2020

Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator

scientific article

Breast cancer in focus: treatment options for triple-negative metastatic breast cancer

scientific article published on January 1, 2012

Capecitabine Monotherapy: Review of Studies in First-Line HER-2-Negative Metastatic Breast Cancer ⬇️

scientific article published on March 14, 2012

Capecitabine and docetaxel in advanced breast cancer: analyses of a phase III comparative trial

scientific article

Capecitabine plus docetaxel combination therapy

scientific article published in June 2005

Capecitabine/Taxane combination therapy: evolving clinical utility in breast cancer

scientific article published on April 2006

Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer

scientific article published on June 2007

Cell Line Derived Multi-Gene Predictor of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer: A Validation Study on US Oncology 02-103 Clinical Trial ⬇️

scientific article published on November 16, 2012

Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs

scientific article published on 28 December 2018

Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases

scientific article published on 29 March 2016

Change in topoisomerase 1 (Top1) positive circulating tumor cells impacts overall survival in patients with advanced breast cancer after treatment with etirinotecan pegol

scientific article published on 4 April 2018

Chemotherapy-induced cognitive dysfunction: a clearer picture

scientific article published on November 2003

Chemotherapy-related cognitive dysfunction in breast cancer

scientific article published on November 2003

Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a Phase II, single-arm,

scientific article published on 07 December 2016

Clinical roundtable monograph. Current treatment options for metastatic breast cancer: what now?

scientific article published in November 2011

Clinical roundtable monograph: effective management of quality of life in metastatic breast cancer

scientific article

Combination paclitaxel (Taxol) and doxorubicin therapy for metastatic breast cancer

scientific article published on October 1994

Commentary concerning demonstration of safety and efficacy of investigational anticancer agents in clinical trials

scientific article

Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer

scientific article

Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evalu

scientific article published on 23 January 2017

Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy

scientific article published in October 2007

Counterpoint: Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancers

scientific article published on 01 July 2003

Current comprehensive assessment and management of women at increased risk for breast cancer

scientific article published on March 2004

Current status of paclitaxel in the treatment of breast cancer

scientific article published on January 1995

Current treatment options for metastatic breast cancer: what now?

scientific article published on 01 November 2011

De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry

scientific article published on 14 October 2019

Dendritic cells, inflammation, and breast cancer

scientific article

Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?

scientific article published on 01 September 2006

Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing

scientific article

Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples.

scientific article

Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL

scientific article published on 11 October 2018

Discordance in management of adverse events associated with oral therapies in hormone receptor–positive breast cancer among health care providers and experts: Findings from an online decision support tool.

scientific article published in 2022

Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.

scientific article published on 9 February 2009

Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: a retrospective review of capecitabine for metastatic breast cancer

scientific article published on December 2011

Dose-intensive therapy for breast cancer

scientific article published on 01 November 1993

Ductal lavage and the clinical management of women at high risk for breast carcinoma: a commentary.

scientific article

Ductal lavage: clinical utility and future promise

scientific article

Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: Results from the phase III BrighTNess trial

scientific article published on 05 October 2019

Early suppressive effects of chemotherapy and cytokine treatment on committed versus primitive haemopoietic progenitors in patient bone marrow

scientific article published on 01 March 1996

Early suppressive effects of chemotherapy on recovery of bone marrow megakaryocyte precursors: possible relationship to platelet recovery

scientific article

Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer ⬇️

scientific article published on 01 August 1995

Effect of tamoxifen on mammographic density

scientific article published in September 2000

Effective management of quality of life in metastatic breast cancer

Effects of alpha-difluoromethylornithine on markers of proliferation, invasion, and apoptosis in breast cancer.

scientific article published on June 2010

Effects of epoetin alfa on cognitive function, mood, asthenia, and quality of life in women with breast cancer undergoing adjuvant chemotherapy

scientific article

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer

scientific article published on 14 March 2017

Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis

scientific article published on 08 July 2020

Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer.

scientific article published on 26 April 2017

Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer

scientific article published on 26 January 2018

Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer

scientific article published on 28 March 2014

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

scientific article published on 2 March 2011

Erratum to: 'Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized con

scientific article published on 3 February 2016

Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.

scientific article published on 7 September 2017

Erythropoietin as a critical component of breast cancer therapy: survival, synergistic, and cognitive applications ⬇️

scientific article published on October 1, 2003

Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial.

scientific article published on 15 October 2015

Evaluating health-related quality-of-life therapeutic effectiveness in a clinical trial with extensive nonignorable missing data and heterogeneous response: results from a phase III randomized trial of gemcitabine plus paclitaxel versus paclitaxel m

scientific article published on September 16, 2011

Evaluation and management of the woman with an abnormal ductal lavage

scientific article

Evaluation of Miracle Mouthwash plus Hydrocortisone Versus Prednisolone Mouth Rinses as Prophylaxis for Everolimus-Associated Stomatitis: A Randomized Phase II Study

scientific article published on 04 March 2019

Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer

scientific article published on 01 August 2020

Everolimus-based combination therapies for HR+, HER2- metastatic breast cancer

scientific article published on 23 July 2018

Extending survival with chemotherapy in metastatic breast cancer

scientific article

Feasibility assessment of a chemoresponse assay to predict pathologic response in neoadjuvant chemotherapy for breast cancer patients

scientific article published on 01 May 2008

Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy

scientific article

First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients.

scientific article

Five-year results of a phase II trial of preoperative 5-fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (wTX) (with trastuzumab in HER2-positive patients) for patients with stage II or III breast cancer.

scientific article published on 26 March 2018

Flow cytometric quantitation of circulating hematopoietic progenitor cells in breast cancer patients on chemotherapy

scientific article published on 01 January 1992

Fulvestrant: clinical application of an estrogen receptor downregulator

scientific article published in January 2002

Gemcitabine and trastuzumab in metastatic breast cancer

scientific article published on April 1, 2003

Gemcitabine combination chemotherapy in metastatic breast cancer: phase II experience.

scientific article published on December 2003

Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment

scientific article published in August 2008

Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer.

scientific article published on 29 December 2010

Gene transfer into hematopoietic cells. Implications for cancer therapy

scientific article published on 01 May 1994

Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities ⬇️

scientific article published on November 19, 2012

Genomic Alterations Associated with Recurrence and TNBC Subtype in High-Risk Early Breast Cancers

scientific article published on 31 August 2018

Genomic alterations in DNA repair and chromatin remodeling genes in estrogen receptor-positive metastatic breast cancer patients with exceptional responses to capecitabine

scientific article

Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer

scientific article published on 6 March 2015

Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer.

scientific article published on 13 June 2019

Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial ⬇️

scientific article

Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2.

scientific article

Highlights from: Third Annual Future of Supportive Therapy in Oncology, San Francisco, CA; 27th Annual, San Antonio Breast Cancer Symposium, San Antonio, TX; 46th Annual Meeting of the American Society of Hematology, San Diego, CA.

scientific article published in April 2005

Highlights in metastatic breast cancer from the 2013 San Antonio Breast Cancer Symposium (SABCS)

scientific article published in March 2014

Highlights in metastatic breast cancer from the 2013 San Antonio Breast Cancer Symposium (SABCS): commentary

Highlights of the 2015 San Antonio Breast Cancer Symposium

Human gene marker/therapy clinical protocols

scientific article published on 01 April 2000

Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer.

scientific article

IL1 Receptor Antagonist Controls Transcriptional Signature of Inflammation in Patients with Metastatic Breast Cancer

scientific article published on 16 July 2018

Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy

scientific article published on 29 January 2016

Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer

scientific article published on 15 March 2011

Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer

scientific article published on 01 June 2019

Impact of prior anthracycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studies

scientific article

Impact of race and tumor subtype on second malignancy risk in women with breast cancer

scientific article

Incidence and Predictive Factors for Recovery of Ovarian Function in Amenorrheic Women in Their 40s Treated With Letrozole

scientific article published on 16 February 2016

Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer ⬇️

scientific article published on January 5, 2011

Ixabepilone and Carboplatin for Hormone Receptor Positive/HER2-neu Negative and Triple Negative Metastatic Breast Cancer

scientific article published on 10 July 2017

Lethal breast cancer

scientific article published on 01 January 2010

Liposomal anthracyclines for breast cancer: overview

scientific article

Local production of lactate, ribose phosphate, and amino acids within human triple-negative breast cancer

scientific article published on 14 April 2021

Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy

scientific article published on 16 April 2015

MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer

scientific article published on 22 May 2017

Management of febrile neutropenia and cardiac toxicity in the adjuvant treatment of breast cancer.

scientific article published on December 2007

Management of premenopausal women with early-stage breast cancer: is there a role for ovarian suppression?

scientific article

Molecular signatures predict outcomes of breast cancer

scientific article published on 01 August 2006

Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers.

scientific article published on 27 April 2012

New perspectives with antimetabolites in the management of breast cancer

scientific article published in January 2004

Novel taxane formulations in the treatment of breast cancer: a thought leader discussion and consensus roundtable

scientific article published on February 2008

Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice

scientific article

Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study ⬇️

scientific article published on June 11, 2012

Overall survival in MERiDiAN, a double-blind placebo-controlled randomised phase III trial evaluating first-line bevacizumab plus paclitaxel for HER2-negative metastatic breast cancer

scientific article published on 23 November 2017

Paclitaxel administration using portable infusion pumps

scientific article published on 01 November 1993

Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients

scholarly article

Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion

scientific article

Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute

scientific article published on 12 October 2015

Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling.

scientific article

Patient-derived xenografts of central nervous system metastasis reveal expansion of aggressive minor clones

scientific article published on 01 January 2020

Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine

scientific article published on 3 June 2015

Pegfilgrastim: recent advances in the prophylaxis of chemotherapy-induced neutropenia

scientific article published on 01 April 2005

Pegylated liposomal doxorubicin in the treatment of breast cancer

scientific article published on December 2003

Pembrolizumab for Early Triple-Negative Breast Cancer

scientific article published on 01 February 2020

Pembrolizumab for Early Triple-Negative Breast Cancer. Reply

scientific article published on 01 June 2020

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

scientific article published on 01 March 2019

Pemetrexed: a promising new treatment for breast cancer.

scientific article

Pemetrexed: an active new agent for breast cancer

scientific article

Perspectives on the mechanism of action and clinical application of eribulin for metastatic breast cancer

scientific article published on 20 March 2019

Pharmacokinetics of piroxantrone in a phase I trial of piroxantrone and granulocyte-colony stimulating factor ⬇️

scientific article published on 01 June 1993

Pharmacokinetics of taxol and doxorubicin administered alone and in combination by continuous 72-hour infusion

scientific article published on 01 January 1994

Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer.

scientific article

Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A

Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer.

scientific article

Phase I clinical trial of alitretinoin and tamoxifen in breast cancer patients: toxicity, pharmacokinetic, and biomarker evaluations

scientific article

Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer

scientific article published on 01 April 1996

Phase I study of Taxol, doxorubicin, plus granulocyte-colony stimulating factor in patients with metastatic breast cancer

scientific article published on 01 January 1993

Phase I study of high-dose piroxantrone with granulocyte colony-stimulating factor ⬇️

scientific article published on September 1, 1993

Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating factor in metastatic breast cancer patients

scientific article

Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer

scientific article

Phase II Study of Eribulin Mesylate Administered Biweekly in Patients With Human Epidermal Growth Factor Receptor-2-negative Metastatic Breast Cancer

scientific article published on 14 October 2019

Phase II randomized trial of weekly and every-3-week ixabepilone in metastatic breast cancer patients.

scientific article published on 29 October 2013

Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

scientific article

Phase II study of fazarabine (NSC 281272) in patients with metastatic colon cancer ⬇️

scientific article published on February 1, 1993

Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer

scientific article published in June 2005

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy

scientific article

Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer

scientific article published in June 2004

Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes

scientific article published in December 2007

Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer

scientific article published on 22 August 2006

Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy

scientific article published on 01 February 2007

Phase II trial of gemcitabine plus trastuzumab in metastatic breast cancer patients previously treated with chemotherapy: preliminary results

scientific article

Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast cancer

scientific article

Phase II trial of weekly docetaxel/ gemcitabine as first-line chemotherapy in patients with locally recurrent or metastatic breast cancer

scientific article published on 01 February 2006

Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin Combined With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive, Early-Stage Breast Cancer

scientific article published on 06 August 2015

Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer

scientific article

Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial

scientific article

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

article

Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer.

scientific article

Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer

scientific article

Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer

scientific article published on 14 August 2020

Pilot study of high dose ICE (ifosfamide, carboplatin, etoposide) chemotherapy and autologous bone marrow transplant (ABMT) with neoR-transduced bone marrow and peripheral blood stem cells in patients with metastatic breast cancer

scientific article published on 01 June 1993

Pilot trial of the safety, tolerability, and retinoid levels of N-(4-hydroxyphenyl) retinamide in combination with tamoxifen in patients at high risk for developing invasive breast cancer

scientific article published on 01 January 2000

Poly (ADP-ribose) polymerase as a novel therapeutic target in cancer

scientific article

Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer.

scientific article

Positive selection of CD34+ hematopoietic cells using an immunoaffinity column results in T cell-depletion equivalent to elutriation

scientific article published on 01 April 1995

Post-chemotherapy and cytokine pretreated marrow stromal cell layers suppress hematopoiesis from normal donor CD34+ cells ⬇️

scientific article published on 01 September 1998

Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications.

scientific article published on 28 April 2015

Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study

scientific article published on 27 October 2020

Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy

scientific article published on 18 December 2018

Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development

scientific article (publication date: 15 April 2005)

Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward

scientific article published on June 2006

Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.

scientific article published on 13 June 2017

Prospective, randomized trial of 5-fluorouracil, leucovorin, doxorubicin, and cyclophosphamide chemotherapy in combination with the interleukin-3/granulocyte-macrophage colony-stimulating factor (GM-CSF) fusion protein (PIXY321) versus GM-CSF in pat

scientific article

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

scientific article published on 7 March 2011

Randomized phase II non-inferiority study (NO16853) of two different doses of capecitabine in combination with docetaxel for locally advanced/metastatic breast cancer

scientific article published on 01 June 2011

Randomized phase-II evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients

scientific article published on 28 October 2019

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

scientific article

Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2-metastatic breast cancer receiving single-agent chemotherapy-a comparison with MONARCH 1

scientific article published on 12 August 2020

Reply to letter to the editor 'Primum non nocere' by Templeton and Šeruga

scientific article published on 7 July 2015

Reprogramming tumor-infiltrating dendritic cells for CD103+ CD8+ mucosal T-cell differentiation and breast cancer rejection

scientific article

Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancer

scientific article

Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer

scientific article published on 25 December 2010

Retroviral gene transduction of adult peripheral blood or marrow-derived CD34+ cells for six hours without growth factors or on autologous stroma does not improve marking efficiency assessed in vivo

scientific article published on 01 June 1997

Retroviral mediated transfer of the human multidrug resistance gene (MDR-1) into hematopoietic stem cells during autologous transplantation after intensive chemotherapy for metastatic breast cancer

scientific article published on 01 July 1994

Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation

scientific article published in June 1995

RiBBON 1 and RiBBON 2: phase III trials of bevacizumab with standard chemotherapy for metastatic breast cancer

scientific article published on 01 August 2008

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.

scientific article published on 7 October 2016

Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial.

scientific article

Sacituzumab Govitecan in Previously Treated Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Final Results from a Phase 1/2, Single-Arm, Basket Trial

scientific article published on 15 September 2020

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer

scientific article published on 01 February 2019

Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: a meta-analysis

scientific article published on 26 December 2014

Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial ⬇️

scientific article published on 08 July 2016

Salvage Chemotherapy for Metastatic Breast Cancer

scientific article published on 01 September 1999

Selection of local therapy after neoadjuvant chemotherapy in patients with stage IIIA,B breast cancer ⬇️

scientific article published on 01 March 1998

Single-agent capecitabine: a reference treatment for taxane-pretreated metastatic breast cancer?

scientific article

Stomatitis Associated With Use of mTOR Inhibitors: Implications for Patients With Invasive Breast Cancer

scientific article published in August 2015

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

scientific article

Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial.

scientific article published in October 2004

Systematic literature review of clinical trials of endocrine therapies for premenopausal women with metastatic HR+ HER2- breast cancer

scientific article published on 09 July 2019

Tamoxifen DownregulatesEtsOncogene Family MembersETV4andETV5in Benign Breast Tissue: Implications for Durable Risk Reduction ⬇️

scientific article published on July 21, 2011

Tamoxifen and fenretinide in women with metastatic breast cancer

scientific article published on 01 October 1999

The Clinical Utility of HER2-Targeted Therapy in the Neoadjuvant Setting: Recent Results From the San Antonio Breast Cancer Symposium ⬇️

scientific article published on 01 February 2011

The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer

scientific article

The addition of hormone therapy to tamoxifen does not prevent hot flashes in women at high risk for developing breast cancer

scientific article published on 13 January 2009

The effect of systemic therapy on local-regional control in locally advanced breast cancer ⬇️

scientific article published on January 1, 1992

The evolving role of capecitabine in breast cancer

scientific article

The global breast cancer burden: variations in epidemiology and survival.

scientific article

The hedgehog pathway in triple-negative breast cancer

scientific article

The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population

scientific article

The progress and promise of molecular imaging probes in oncologic drug development

scientific article published in November 2005

Transforming growth factor-beta s in mammary tumorigenesis: promoters or antipromoters?

scientific article published on January 1995

Transforming growth factor-beta1 circulates in normal human plasma and is unchanged in advanced metastatic breast cancer

scientific article published on 01 January 1995

Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development

scientific article published on 01 February 2002

Treatment effect of capecitabine and docetaxel or docetaxel alone by oestrogen receptor status in patients with metastatic breast cancer: results of an exploratory analysis

scientific article published on 2 October 2013

Treatment for anthracycline-pretreated metastatic breast cancer

scientific article

Treatment options for patients with HR+/HER2- advanced breast cancer during the COVID-19 pandemic: dose reduction of ribociclib does not diminish efficacy

scientific article published on 20 May 2020

Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial

scientific article published on 28 September 2019

Tumour and cellular distribution of activated forms of PR in breast cancers: a novel immunohistochemical analysis of a large clinical cohort

scientific article published on 22 August 2016

Typhlitis resulting from treatment with taxol and doxorubicin in patients with metastatic breast cancer

scientific article published on 01 March 1993

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

scientific article published on 01 November 2019

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.

scientific article

nab-Paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis ⬇️

scientific article published on April 6, 2013

nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial

scientific article published on 01 August 2018

Paulina is supported by:

About Paulina

Help